IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	**09/762,587**	Group Art Unit:	1642
Confirmation No.:	5272	Examiner:	M.T. Davis
Filed (§ 371):	06 September 2001		
Applicant:	Antonio J. GRILLO-LÓPEZ		
For:	Use of Radiolabeled Anti-CD20 Antibody to Treat Rituximab-Refractory B-Cell Lymphoma (as amended)		

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the information listed on the Form PTO-1449 that accompanies this paper and the pending patent applications identified below. Applicant does not represent that a search has been conducted or that the cited documents are prior art against the claims in this application. Copies of the cited non-U.S. patent documents accompany this submission.

This disclosure statement is filed under the provisions of 37 C.F.R. § 1.97(c)(2) prior to the mailing date of a final action on the merits. Applicant requests that the Director charge the required fee (§ 1.17(p)) of **$180**, as well as any other fees as may be required for consideration of this paper, to our **Deposit Account No. 18-1260**.

Copending patent applications

In addition to the information cited on the Form PTO-1449 that accompanies this paper, applicant directs the examiner's attention to the commonly-owned pending U.S. patent applications listed below.

Serial No.	Filing Date	First Inventor
09/436,347	09 Nov 1999	White
09/628,187	28 Jul 2000	White
09/911,692	25 Jul 2001	Anderson
09/911,703	25 Jul 2001	Anderson
10/196,732	17 Jul 2002	Grillo-López
10/238,681	11 Sep 2002	Anderson
10/440,186	19 May 2003	Grillo-López
10/850,712	21 May 2004	Grillo-López

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE
	D1	Re 38,008	25 Feb 2003	Abrams			
	D2	4,975,278	4 Dec 1990	Senter			
	D3	5,439,665	8 Aug 1995	Hansen			
	D4	5,595,721	21 Jan 1997	Kaminski			
	D5	5,648,267	15 Jul 1997	Reff			
	D6	5,677,171	14 Oct 1997	Hudziak			
	D7	5,686,072	11 Nov 1997	Uhr			
	D8	5,691,320	25 Nov 1997	van Borstel			
	D9	5,693,780	2 Dec 1997	Newman			
	D10	5,776,456	7 Jul 1998	Anderson			
	D11	5,399,061	1 Dec 1998	Anderson			
	D12	6,682,734 B1	27 Jan 2004	Anderson			
	D13	6,893,625 B1	17 May 2005	Robinson			
	D14	2002/ 0009444 A1	24 Jan 2002	Grillo-López			
	D15	2002/ 0197255 A1	26 Dec 2002	Anderson			
	D16	2003/ 0021781 A1	30 Jan 2003	Anderson			
	D17	2003/ 0026804 A1	24 Feb 2003	Grillo-López			
	D18	2003/ 0082172 A1	1 May 2003	Anderson			
	D19	2003/ 0095963 A1	22 May 2003	Anderson			
	D20	2003/ 0206903 A1	6 Nov 2003	Grillo-López			
	D21	2004/ 0167319 A1	26 Aug 2004	Teeling			
	D22	2004/ 0213784 A1	28 Oct 2004	Grillo-López			

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE
	D23	2005/ 0163708 A1	28 July 2005	Robinson			
	D24	2005/ 0186205 A1	25 Aug 2005	Anderson			
	D25	2006/ 0034835 A1	16 Feb 2006	Adams			

FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB	TRANSLATION	
	D26	0 125 023 A1	14 Nov 1994	EP				
	D27	0 173 494 A2	5 May 1986	EP				
	D28	0 274 394 A2	13 Jul 1988	EP				
	D29	0 451 216 B1	24 Jan 1996	EP				
	D30	0 669 836 B1	7 Mar 1996	EP				
	D31	0 510 949 A2	28 Oct 1992	EP				
	D32	0 682 040 A1	15 Nov 1995	EP				
	D33	0 752 248 A1	8 Jan 1997	EP				
	D34	91/ 04320 A1	4 Apr 1991	WO				
	D35	92/ 07466 A1	14 May 1992	WO				
	D36	93/ 02108 A1	4 Feb 1993	WO				
	D37	94/11026 A2	26 May 1994	WO				
	D38	00/ 09160 A1	24 Feb 2000	WO				
	D39	00/ 27428 A1	18 May 2000	WO				
	D40	00/ 27433 A1	18 May 2000	WO				
	D41	01/ 10460 A1	15 Feb 2001	WO				
	D42	2004/ 056312 A2	8 Jul 2004	WO				

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	D43	Adams R.A. *Cancer Res.* 27: 2479-82, 1967. Formal discussion: the role of transplantation in the experimental investigation of human leukemia and lymphoma.
	D44	Adams R.A. et al. *Cancer Res.* 28(6): 1121-25, 1968. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2.
	D45	Almasri N.M. et al. *Am. J. Hematol.* 40: 259-63, 1992. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
	D46	Anderson D.R. et al. Second IBC Int'l. Conference on Antibody Engineering, San Diego, 16-18 December 1991. Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody (abstract of presentation).
	D47	Anderson K.C. et al. *Blood* 63(6): 1424-33, 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
	D48	Appelbaum F.R. *Hem. Onc. Clin. N. Amer.* 5(5): 1013-25, 1991. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
	D49	Armitage J.O. et al. *Cancer* 50: 1695-1702, 1982. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
	D50	Armitage J.O. et al. *J. Clin. Oncol.* 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
	D51	Badger C.C. et al. *Cancer Res.* 46: 6223-28, 1986. Experimental radioimmunotherapy of murine lymphoma with ^{131}I-labeled anti-T-cell antibodies.
	D52	Beychok S. (in) *Cells of Immunoglobulin Synthesis*, B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of *in vitro* and cellular assembly of immunoglobulins.
	D53	Bhan A.K. et al. *J. Exp. Med.* 154: 737-49, 1981. Stages of B cell differentiation in human lymphoid tissue.
	D54	*Biogen Idec Inc. v. Corixa Corp.,* Case No. 01-CV-1637 IEG (RBB), Stipulation of Dismissal of Claims and Counterclaims with Prejudice and Order (S.D.Cal., May 13, 2004).

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D55	Boulianne G.L. et al. *Nature* 312: 643-46, 1984. Production of functional chimaeric mouse/human antibody.
	D56	Brunner K.T. et al. *Immunology* 14(2): 181-96, 1968. Quantitative assay of the lytic action of immune lymphoid cells on ^{51}Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.
	D57	Buchsbaum D.J. et al. *Cancer Res.* 50: 993s-999s, 1990. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
	D58	Buchsbaum D.J. et al. *Cancer Res.* 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
	D59	Buchsbaum D.J. et al. *Cancer Res.* 52: 6476-81, 1992. Therapy with unlabeled and ^{131}I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
	D60	Buchsbaum D.J. et al. *I.J. Rad. Oncol. Biol. Phys.* 18: 1033-41, 1990. A comparison of ^{131}I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
	D61	Buchsbaum D.J. et al. *I.J. Rad. Oncol. Biol. Phys.* 25(4): 629-38, 1993. Comparison of ^{131}I- and ^{90}Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
	D62	Byrd J.C. *Cancer Biother. Radiopharm.* 14(4)L 323, 1999. Rituximab therapy in patients with chronic lymphocytic leukemia.
	D63	Byrd J.C. et al. *J. Clin. Oncol.* 17(3): 791-795, Mar. 1999. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
	D64	Calvert J.E. et al. *Semin. Hematol.* 21(4): 226-243, 1984. Cellular events in the differentiation of antibody-secreting cells.
	D65	Carrasquillo J.A. et al. *J. Nucl. Med.* 26: 67, abst. no. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody.
	D66	Chen J.J. et al. *J. Immunol.* 143(3): 1053-57, 1989. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D67	Chinn P. et al. *Proc. Ann. Mtg. Am. Assn. Cancer Res.* 33: 337, abst. no. 2012, 1992. Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma.
	D68	Chomczynki P. et al. *Anal. Biochem.* 162: 156-59, 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
	D69	Clark E.A. et al. *J. Cell. Biochem.* (Suppl. 9A): 63, 1985. Anti-Bp35 antibody induces human B cell proliferation: implications for *in vivo* immunotherapy.
	D70	Clark E.A. et al. *Proc. Natl. Acad. Sci. USA* 82(6): 1766-70, 1985. Role of the Bp35 cell surface polypeptide in human B-cell activation.
	D71	Classon B.J. et al. *J. Exp. Med.* 169(4): 1497-1502, 1989. The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OC-44 antigen.
	D72	Cogliatti S.B. et al. *Sw. Med. Weekly* 192: 607-17, 2002. Who is *WHO* and what was *REAL*?
	D73	Coiffer B. *Ann. Oncol.* 83(Suppl 1): S73-S74, 2004. New treatment strategies in lymphomas: aggressive lymphomas.
	D74	Coiffier B. et al. *N. Engl. J. Med.* 346(4): 235-42, 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
	D75	Coleman M. et al. *Blood* 102(11 pt.1): 29a, abst. no. 29, 2003. The BEXXAR® therapeutic regimen (tositumomab and Iodine I-131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/ refractory disease, and rituximab-naïve disease.
	D76	Cope. *Oncology* 8(4): 100, 1994. Antibody shows promise in treating B-cell lymphoma.
	D77	Davis T.A. et al. *Blood* 92(10 Suppl. 1): 414a, abst. no. 1711, Nov. 1998. Rituximab: first report of a phase II (PII) trial in NHL patients (PTS) with bulky disease.
	D78	DeNardo G.L. et al. *Cancer Res.* 50(3 Suppl.): 1014s-1016s, 1990. Fractionated radioimmunotherapy of B-cell malignancies with ^{131}I-Lym-1.
	D79	DeNardo G.L. et al. *I.J. Rad. Oncol. Biol. Phys.* 11(2): 335-48, 1985. Requirements for a treatment plan in system for radioimmunotherapy.
	D80	DeNardo S.J. et al. *Antibody Immunoconj. Radiopharm.* 1(1): 17-33, 1988. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody.
	D81	DeNardo S.J. et al. *Cancer* 73(3 Suppl.): 1023-32, 1994. The biologic window for chimeric L6 radioimmunotherapy.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D82	Dickson S. *Gen. Engr. News* 5(3): 1, March 1985. Scientists produce chimeric monoclonal Abs.
	D83	Eary J.F. et al. *J. Nuc. Med.* 31(8): 1257-68, 1990. Imaging and treatment of B-cell lymphoma.
	D84	Einfeld D.A. et al. *EMBO J.* 7: 711-17, 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.
	D85	Ford et al. *Highlights in Oncology Practice* 16(2): 40-50, 1998. Immunotherapeutic approaches to treatment of B-cell neoplasms: focus on unconjugated antibodies.
	D86	Freedman A.S. et al. *J. Clin. Oncol.* 8: 784-91, 1990. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
	D87	Friedberg J.W. et al. *Expert Rev. Anticancer Ther.* 4(1): 18-26, 2004. Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
	D88	Golay J.T. et al. *J. Immunol.* 135(6): 3795-801, 1985. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.
	D89	Goldenberg D.M. et al. *J. Clin. Oncol.* 9(4): 548-64, 1991. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies.
	D90	Greenberger J.S. et al. *Cancer Res.* 45(2): 758-67, 1985. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
	D91	Grillo-López A.J. et al. *Br. J. Haematol.* 93(Suppl. 2): 283, abst. no. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB): safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL).
	D92	Harris N.L. et al. *Blood* 54(5): 1361-92, 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
	D93	Harris N.L. et al. *J. Clin. Oncol.* 17(12): 3835-49, 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting–Airlie House, Virginia, November 1997.
	D94	Hekman A. et al. *Ann. Rept. Netherlands Cancer Inst., Amsterdam*, pages 47-48,1993. Immunotherapy.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D95	Herold M. et al. *Ann. Hematol.* 79: 332-335, 2000. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab.
	D96	Hiddemann W. et al. *Blood* 88(11): 4085-89, 1996. Lymphoma classification–the gap between biology and clinical management is closing.
	D97	Hooijberg E. et al. *Cancer Res.* 55: 2627-34, 1995. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
	D98	IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for RITUXAN® approved by U.S. Food and Drug Administration on 26 November 1997.
	D99	IDEC Pharmaceuticals Corp., U.S. Securities and Exchange Commission Form S-1 Registration Statement, 1991.
	D100	Juweid M. et al. *Cancer Res.* 55(23 Suppl.): 5827s-5831s, 1995. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
	D101	Kaminski M.S. et al. *Antibody Immunoconj. Radiopharm.* 5(3): 345, abst. no. 57, 1992. Initial clinical radioimmunotherapy results with ^{131}I-anti-B1 (anti-CD20) in refractory B-cell lymphoma."
	D102	Kaminski M.S. et al. *Blood* 78(10 Suppl. 1): 43a, abst. no. 161, 1992. Radioimmunotherapy (RIT) of refractory B-cell lymphoma with 131-I-anti-B1 (anti-CD20) antibody: promising early results using non-marrow ablative radiation doses.
	D103	Kaminski M.S. et al. *N. Engl. J. Med.* 329: 459-65, 1993. Radioimmunotherapy of B-cell lymphoma with [^{131}I]anti-B1 (anti-CD20) antibody.
	D104	Kinoshita T. et al. *J. Clin. Oncol.* 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
	D105	Langmuir V.K. *Nucl. Med. Biol.* 19(2): 213-55, 1992. Radioimmunotherapy: clinical results and dosimetric considerations.
	D106	Larson S.M. et al. *Nucl. Med. Biol.* 16: 153-58, 1989. Comparison of bone marrow dosimetry and toxic effect of high dose ^{131}I-labeled monoclonal antibodies administered to man.
	D107	Leichner P.K. et al. *Front. Rad. Ther. Oncol.* 24: 109-20, 1990. Dosimetry and treatment planning in radioimmunotherapy.
	D108	Leichner P.K. et al. *Med. Phys.* 20(2): 529-34, 1993. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D109	Levy R. et al. *Fed. Proc.* 42: 2650-56, 1983. Tumor therapy with monoclonal antibodies.
	D110	Ling N.R. et al. (in) *Leucocyte Typing III: White Cell Differentiation Antigens*, A.J. McMichael et al., eds., Oxford: Oxford Univ. Pr., 1987, pp. 302-35. B-cell and plasma cell antigens: new and previously defined clusters.
	D111	Link M.P. et al. *J. Immunol.* 137(9): 3013-18, 1986. A unique antigen on mature B-cells defined by a monoclonal antibody.
	D112	Lipton J.M. et al. *Blood* 60(5 Suppl. 1): 170a, abst. no. 609, 1992. Distribution of B1, CALLA, β2 microglobulin and Ia on hematopoiesis supporting cells (HSC) in short and long-term cultures.
	D113	Liu A.Y. et al. *J. Immunol.* 139(10): 3521-26, Nov. 1987. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
	D114	Lonberg N. et al. *Nature* 368: 856-59, 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications
	D115	Lowman H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential activities in a series of humanized anti-CD20 antibodies.
	D116	Macey D.J. et al. *Front. Rad. Ther. Oncol.* 24: 123-31, 1990. A treatment planning program for radioimmunotherapy.
	D117	Macklis R.M. et al. *Antibody Immunoconj. Radiother.* 5(3): asbst. no. 39, 1992. Induction of programmed cell death in malignant lymphomas after radioimmunotherapy.
	D118	Macklis R.M. et al. *Cancer* 73(3 Suppl.): 966-73, 1994. Radiobiologic studies of low-dose-rate ^{90}Y-lymphoma therapy.
	D119	Maloney D.G. et al. *Blood* 80(6): 1502-1510, 1992. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
	D120	Maloney D.G. et al. *Blood* 88(10: Suppl. 1): 637a, abst. no. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.
	D121	Mariuzza et al. *Science*. 233: 747-753, 1986. Three-dimensional structure of an antigen-antibody comple at 2.8 A resolution.
	D122	Marx J.L. *Science* 229(4712): 455-56, 1985. Antibodies made to order.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D123	Masucci G. et al. *Med. Oncol. Tumor Pharmacother.* 8(3): 207-20, 1991. Chemotherapy and immunotherapy of colorectal cancer.
	D124	McLaughlin P. et al. *Oncology* 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas.
	D125	Meredith R.F. et al. *J. Nucl. Med.* 33(9): 1648-53, 1992. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
	D126	Mishell B.E. et al., eds. *Selected Methods in Cellular Immunology*, San Francisco: Freeman (1980), p. 287-304. Modification and use of antibodies to label cell surface antigens.
	D127	Morrison S. et al. *Proc. Nat'l Acad. Sci. USA* 81: 6851-54, 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
	D128	Morrison S.L. *Science* 229: 1202-07, 1985. Transfectomas provide novel chimeric antibodies.
	D129	Multani P.S. et al. *J. Clin. Oncol.* 16(11): 3691-3710, 1998. Monoclonal antibody-based therapies for hematologic malignancies.
	D130	Munro A. *Nature* 312: 597, 1984. Uses of chimeric antibodies.
	D131	Murray J.L. et al. *J. Nucl. Med.* 26: 3328-29, 1985. The effect of radionuclide dose on imaging with indium-111-labeled anti P-97 monoclonal antibody.
	D132	Nadler L.M. et al. *Cancer Res.* 40(9): 3147-54, 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.
	D133	Nadler L.M. et al. *J. Clin. Invest.* 67: 134-140, 1981. A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
	D134	Nadler L.M. et al. *J. Clin. Invest.* 74(2): 332-40, 1984. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.
	D135	Nadler L.M. et al. *Lancet* 2(8400): 427-31, 1984. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma.
	D136	Neuberger M.S. et al. *Nature* 314: 268-70, 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function.
	D137	Non-Hodgkin's Lymphoma Pathologic Classification Project. *Cancer* 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D138	Oettgen H.C. et al. *Hybridoma* 2(1): 17-28, 1983. Further biochemical studies of the human B-cell differentiation antigens B1 and B2.
	D139	Oncology Nursing Society. onsopcontent.ons.org/oes/online_ce/lymph/.05-classification.htm, retrieved 25 February 2003. Current therapies and future directions in the treatment of non-Hodgkin's lymphoma.
	D140	Ozato K. et al. *J. Immunol.* 126(1): 317-21, 1981. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.
	D141	Panka et al. *Proc. Nat'l. Acad. Sci.* 85: 3080-3084, 1988. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies.
	D142	Parker B.A. et al. *Cancer Res.* 50(3): 1022s-1028s, 1990. Radioimmunotherapy of human B-cell lymphoma with ^{90}Y-conjugated antiidiotype monoclonal antibody.
	D143	Pearson J.W. et al. *Cancer Res.* 49(18): 4990-95, 1989. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
	D144	Polyak M.J. et al. *Blood* 99: 3256-62, 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
	D145	Press O. et al. *Proc. Ann. Mtg. ASCO* 5: 221, abst. no. 864, 1986. Serotherapy of malignant B cell lymphomas with monoclonal antibody 1F5 (anti-CD20).
	D146	Press O.W. et al. *Adv. Exp. Med. Biol.* 303: 91-96, 1991. Radiolabeled antibody therapy of human b cell lymphomas.
	D147	Press O.W. et al. *Cancer Res.* 49(17): 4906-12, 1989. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
	D148	Press O.W. et al. *J. Clin. Oncol.* 7(8): 1027-38, 1989. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
	D149	Press O.W. et al. *N. Engl. J. Med.* 329(17): 1219-23, 1993. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
	D150	Reff M. et al. *J. Cell. Biochem.* Suppl. 17E: 260, abst. no. T103, 1993. Depletion of B cells *in vivo* by a chimeric mouse human monoclonal antibody to CD20.
	D151	Reilly R.M. *Clin. Pharm.* 10: 359-75, 1991. Radioimmunotherapy of malignancies.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D152	Robinson R. et al. *Human Antibody Hybrid.* 2: 84-93, Apr. 1991. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.
	D153	Rottenburger C. et al. *Br. J. Haematol.* 106(2): 545-52, 1999. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation.
	D154	Rudikoff et al. *Proc. Nat'l. Acad. Sci* 79: 1979-1983, 1982. Single amino acid substitution altering antigen-binding specificity.
	D155	Sahagan B.G. et al. *J. Immunol.* 137: 1066-74, 1986. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
	D156	Scharff M. *Harvey Lectures* 69: 125-42, 1974. The synthesis, assembly, and secretion of immunoglobulin: a biochemical and genetic approach.
	D157	Schlom J. et al. *J. Natl. Cancer Inst.* 82(9): 763-71, 1990. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
	D158	Schwartz-Albiez R. et al. *J. Immunol.* 140(3): 905-14, 1988. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein.
	D159	Seaver, S. *Genetic Engineering News.* 19 and 21, 1982. Monoclonal antibodies in industry: more difficult than originally thought.
	D160	See-Lasley K. et al. Manual of Oncology Therapeutics. St. Louis: C.V. Mosby Co., pages 44-71, 1981. Hodgkin's disease and non-Hodgkin's lymphoma.
	D161	Senter P.D. *FASEB J.* 4: 188-93, 1990. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
	D162	Senter P.D. et al. *Adv. Exp. Med. Biol.* 303: 97-105, 1991. Activation of prodrugs by antibody-enzyme conjugates.
	D163	Senter P.D. et al. *Cancer Res.* 49: 5789-92, 1989. Enhancement of the *in vitro* and *in vivo* antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
	D164	Sharkey R.M. et al. *Cancer Res.* 50(3): 964s-969s, 1990. Biological considerations for radioimmunotherapy.
	D165	Shulman M. et al. *Nature* 276(5685): 269-72, 1978. A better cell line for making hybridomas secreting specific antibodies.

EXAMINER	**DATE CONSIDERED**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D166	Smeland E.B. et al. *J. Immunol.* 138(10): 3179-84, 1987. Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.
	D167	Srivastava S.C. et al. *Nucl. Med. Biol.* (*I.J. Rad. Appl. Instrum. B*) 18(6): 589-603, 1991. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies.
	D168	Stashenko P. et al. *J. Immunol.* 125(4): 1678-85, 1980. Characterization of Human B Lymphocyte-Specific Antigen.
	D169	Staudt L.M. et al. Manuscript from pubmedcentral at NIH, edited paper published at *Adv. Immunol.* 87: 163-208, 2005. The biology of human lymphoid malignancies revealed by gene expression profiling.
	D170	Stewart J.S.W. et al. *Int. J. Cancer* Suppl. 3: 71-76, 1988. Intraperitoneal ^{131}I- And ^{90}Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
	D171	Sun L.K. et al. *Hybridoma* 5(Suppl. 1): S17-20, 1986. Chimeric antibodies with 17-1A-derived variable and human constant regions.
	D172	Tan L.K. et al. *J. Immunol.* 135: 3564-67, 1985. A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells.
	D173	Tedder T.F. et al. *Eur J. Immunol.* 16(8): 881-87, 1986. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes.
	D174	Tedder T.F. et al. *J. Immunol.* 135(2): 973-79, 1985. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
	D175	Tedder T.F. et al. *J. Immunol.* 141(12): 4388-94, 1988. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19.
	D176	Teeling J.L. et al. *Blood* 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
	D177	Teeling J.L. et al. *J. Immunol.* 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
	D178	Tsai D.E. et al. *Bone Marrow Transplant.* 24(5): 521-26, 1999. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01186	**Serial No:**	**09/ 762,587**
	Inventor(s):	A.J. GRILLO-LÓPEZ	Examiner:	M.T. DAVIS
	Filed:	06 September 2001	Art Unit:	1642

INITIAL	INDEX	CITATION
	D179	Tsai D.E. et al. *Clin. Lymphoma Myeloma* 1(1): 62-66, 2000. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy.
	D180	Uckun F.M. et al. *Cancer Res.* 45(1): 69-75, 1985. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
	D181	Uckun F.M. et al. *J. Immunol.* 134(5): 3504-15, 1985. Combined *ex vivo* treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
	D182	Urlaub, G. et al. *Som. Cell. Mol. Genet.* 12(6): 555-66, 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions.
	D183	Valentine M.A. et al. *J. Biol. Chem.* 264: 11282-87, 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.
	D184	Vartholomatos G. et al. *Acta Haematol.* 102: 94-98, 1999. Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.
	D185	Verkh L.I. et al. *Proc. Ann. Mtg. ASCO* 17: abst. no. 154, 1998. Dosimetry results of ONCOLYM™ in the treatment of refractory B cell non-Hodgkin's lymphoma (NHL).
	D186	Vose J.M. et al. *J. Clin. Oncol.* 19(2): 389-97, 2001. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
	D187	Wessels B.W. et al. *Med. Phys.* 11(5): 638-45, 1984. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
	D188	Witzig T.E. et al. *J. Clin. Oncol.* 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
	D189	Yang H. et al. *Am. J. Hematol.* 62: 247-50, 1999. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

EXAMINER	**DATE CONSIDERED**
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	**SHEET 13 OF 13**